Novavax Inc. ($NVAX) Stock Forecast: Down 5.5% Today

What is Novavax Inc.?

Novavax Inc. (NASDAQ: NVAX) is a biotechnology company specializing in vaccine development for infectious diseases. The stock faced significant downward movement in the market today.

Why is Novavax Inc. going down?

NVAX stock is down 5.5% on May 21, 2025 15:06

• Novavax's stock saw a decline despite obtaining FDA approval for its COVID-19 vaccine, Nuvaxovid, which received limited approval specifically for high-risk groups and seniors.
• The FDA's decision to restrict annual COVID-19 booster approvals to high-risk individuals and request further trials for healthy adults may have influenced investor sentiment negatively towards Novavax's stock.
• The market's response could be linked to the stricter clinical trial standards set by the FDA, potentially causing concerns about Novavax's upcoming vaccine projects and commercialization prospects.
• Despite achieving a regulatory milestone and receiving a milestone payment from partner Sanofi SA, the market's emphasis on limited approval and safety evaluations likely contributed to the bearish movement in NVAX stock.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr. - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )

The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.

https://www.benzinga.com/government/regulations/25/05/45537919/fda-limits-annual-covid-19-boosters-to-high-risk-americans-demands-new-trials-for-healthy-

Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment - Novavax ( NASDAQ:NVAX ) , Sanofi ( NASDAQ:SNY )

Novavax Inc. NVAX has received limited approval from the U.S. Food and Drug Administration for its COVID-19 vaccine, Nuvaxovid, marking a regulatory milestone and unlocking a $175 million milestone payment from partner Sanofi SA SNY. The protein-based vaccine, distinct from mRNA options by Pfizer ...

https://www.benzinga.com/25/05/45496095/novavax-scores-key-fda-win-shares-jump-19-as-sanofi-milestone-unlock

NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.

https://www.zacks.com/stock/news/2474024/nvax-stock-surges-on-securing-fda-approval-for-covid-19-vaccine

Novavax Wins Limited FDA Nod For COVID Shot-Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny - Novavax ( NASDAQ:NVAX ) , BioNTech ( NASDAQ:BNTX )

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s NVAX COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase the risk of severe illness.

https://www.benzinga.com/government/regulations/25/05/45488265/novavax-wins-limited-fda-nod-for-covid-shot-cleared-only-for-seniors-high-risk-groups-amid

Trending Today

Memecoin ($MEME) Crypto Forecast: Down 6.3% Today

Aave ($AAVE) Crypto Forecast: Down 5.2% Today

Pepe ($PEPE) Crypto Forecast: Down 6.7% Today

Decentraland ($MANA) Crypto Forecast: Down 5.1% Today

Arbitrum ($ARB) Crypto Forecast: Down 5.3% Today

EOS ($EOS) Crypto Forecast: Up 6.0% Today

Ethena ($ENA) Crypto Forecast: Down 5.3% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Avalanche ($AVAX) Crypto Forecast: Down 5.0% Today

Stox ($STX) Crypto Forecast: Down 5.0% Today

Novavax Inc. Price History

23.03.2025 - NVAX Stock was up 19.5%

• Despite a market dip, Novavax (NVAX) managed to gain, showcasing its resilience and potential strength in the market.
• The positive movement in Novavax's stock could be attributed to potential positive news regarding its vaccine development or progress in clinical trials.
• Investors might be optimistic about Novavax's future prospects, leading to increased buying activity and driving the stock price higher.
• This divergence from the overall market trend suggests that investors have confidence in Novavax's ability to deliver results and make significant advancements in the healthcare sector.

08.04.2025 - NVAX Stock was up 13.9%

• Novavax (NVAX) saw a substantial bullish upturn after exceeding earnings and revenue expectations by a significant margin in the first quarter.
• The market responded favorably to Novavax's exceptional quarterly earnings and revenue beat, indicating investor trust in the company's progress and future prospects.
• The upbeat financial outcomes and potential pipeline advancements announced during the earnings call likely contributed to the positive momentum in NVAX stock.
• In conclusion, Novavax's strong performance and optimistic market sentiment steered the stock towards a bullish path, underscoring the company's resilience and growth potential within the biotechnology industry.

08.04.2025 - NVAX Stock was up 16.2%

• Novavax (NVAX) exceeded both earnings and revenue estimates for the first quarter of 2025, showcasing strong financial performance.
• The positive earnings surprise likely boosted investor confidence in the company's growth prospects, leading to the bullish movement in the stock.
• Investors are eagerly awaiting pipeline updates from Novavax, indicating optimism about the company's future projects and potential market impact.
• The flat performance of Novavax in the previous trading session amidst overall market gains suggests that today's bullish movement was primarily driven by the impressive earnings report rather than broader market trends.

11.03.2025 - NVAX Stock was up 13.2%

• The bullish movement in NVAX stock could be attributed to the positive market sentiment driven by the company's recent jump in share price and optimistic earnings estimate revisions.
• Despite concerns raised by the HHS Secretary regarding the efficacy of Novavax's COVID-19 vaccine, investors seem to be focusing on the potential strength and upside in the stock.
• The market might be interpreting the concerns as an opportunity for Novavax to address any issues and improve its vaccine, leading to increased confidence in the company's future prospects.
• The overall positive trend in NVAX stock reflects investor confidence in the company's ability to navigate challenges and capitalize on opportunities in the biotechnology sector.

19.04.2025 - NVAX Stock was down 5.6%

• The company received limited approval from the FDA for its COVID-19 vaccine, Nuvaxovid, with restrictions on usage for specific age groups and high-risk individuals.
• Despite securing FDA approval, the stock faced a bearish trend, possibly due to concerns about the limited target population for the vaccine.
• The milestone payment of $175 million from partner Sanofi SA did not seem to have a positive impact on the stock's performance.
• The market may be reacting to the news of FDA approval with new conditions, leading to uncertainty about the vaccine's widespread adoption and revenue potential.

19.04.2025 - NVAX Stock was down 6.7%

• Novavax's stock experienced a bearish movement despite the FDA granting limited approval for its COVID-19 vaccine.
• The restricted use of the vaccine to specific age groups and high-risk individuals might have raised concerns about the company's market potential and revenue prospects.
• Investors may be disappointed by the limited scope of the FDA approval, leading to a sell-off of NVAX shares as they reassess the company's position in the competitive vaccine market.
• The market reaction suggests that investors were expecting broader approval for Novavax's vaccine, and the current restrictions could impact the company's ability to capture a larger market share and generate significant revenue.

24.03.2025 - NVAX Stock was down 6.3%

• Despite positive updates on Novavax's COVID-19 vaccine progress towards FDA approval and its lower incidence of side effects relative to rivals, the stock trended bearishly.
• Following a recent spike in share value, profit-taking actions by investors might have contributed to today's downturn.
• While Novavax closed slightly above the previous day's numbers, the broader market decline likely played a role in the stock's bearish performance.

09.04.2025 - NVAX Stock was down 12.2%

• Novavax (NVAX) reported impressive first-quarter earnings and revenue beats, with a significant increase in revenues recognized from the termination of advanced purchase agreements.
• Despite the positive financial results, the market may have reacted bearishly due to profit-taking after a recent rally in the stock price.
• Investors might be uncertain about the stock's future performance, considering the focus on pipeline updates during the earnings call and the overall market sentiment.

16.03.2025 - NVAX Stock was down 5.6%

• Novavax's stock fell more than the broader market, closing at $6.39 with a -0.31% move from the previous day.
• A study revealed that Novavax's Covid vaccine showed milder side effects compared to Pfizer-BioNTech's shot, which could have impacted market sentiment.
• The stock took a hit as the HHS Secretary raised concerns about the efficacy of Novavax's protein-based Covid-19 vaccine in a recent interview.
• The combination of market factors such as comparative vaccine side effects and regulatory concerns likely contributed to the bearish movement in Novavax's stock today. Investors may be reacting to the perceived challenges facing the company in the competitive vaccine landscape.

21.04.2025 - NVAX Stock was down 5.5%

• Novavax's stock saw a decline despite obtaining FDA approval for its COVID-19 vaccine, Nuvaxovid, which received limited approval specifically for high-risk groups and seniors.
• The FDA's decision to restrict annual COVID-19 booster approvals to high-risk individuals and request further trials for healthy adults may have influenced investor sentiment negatively towards Novavax's stock.
• The market's response could be linked to the stricter clinical trial standards set by the FDA, potentially causing concerns about Novavax's upcoming vaccine projects and commercialization prospects.
• Despite achieving a regulatory milestone and receiving a milestone payment from partner Sanofi SA, the market's emphasis on limited approval and safety evaluations likely contributed to the bearish movement in NVAX stock.

06.04.2025 - NVAX Stock was down 6.9%

• Novavax (NVAX) saw significant bearish movement today, potentially a result of profit-taking following recent gains or concerns about the upcoming earnings.
• Investors may have responded unfavorably to the lack of substantial changes in NVAX's stock price yesterday, leading to increased selling activity.
• Expectations may have been elevated due to focus on pipeline updates during the earnings call, and any perceived shortcomings in those updates could have contributed to the market downturn.
• Although market gains were stagnant, the decrease in NVAX's stock price may also reflect broader investor sentiment towards the biotechnology field and vaccine stocks as a whole.

29.03.2025 - NVAX Stock was down 7.0%

• The bearish movement in NVAX stock today could be attributed to the request for new trials for Novavax's COVID vaccine by former FDA appointees, possibly causing a delay in approval.
• Despite the recent positive developments and surge in NVAX stock price, uncertainty around the new clinical trials request may have unsettled investors, resulting in the downward trend.
• Investors seem wary of the potential consequences of a delayed approval and its effects on Novavax's competitiveness in the COVID-19 vaccine market, adding to the stock's downward pressure.